1. AstraZeneca, Lilly, Sanofi, and others raise prices to start July — Merck gets a CRL from FDA on Keytruda for hepatocellular carcinoma — 2020 biotech IPOs continue to break records — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

All you job seekers need to know about Otonomy

Discussion in 'Otonomy' started by anonymous, Mar 15, 2017 at 3:16 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Here's a basic timeline to get you up to speed.

    February 2016: New hire options granted, everyone is excited. That is, until they hit the field after training. Within 2 weeks, virtually everyone knows that this company is toast. Seriously. Look at the quarterly results since. There is no market here.

    May 2016: Request us to do a stupid survey on Otiprio sample usage. No doctors do the survey. The reps complete it, because the morons in the executive suite are too stupid to realize that it takes more than a couple of days for doctors to actually form an opinion of the drug and they want the results, like immediately, so DW can go on marching to analysts a continuous flow of utter bullshit.

    June 2016: Reps across the country make up formulary wins to get paid, because they know they will never sell any significant volume of this product called Otiprio (ciprofloxacin otic suspension) 6%. There you go compliance...was that done correctly? And yes, half the organization made shit up about the surveys and the formulary wins. Otherwise, don't you think more Otiprio would be being used, right idiots?

    July 2016: After numerous pathetic conference calls by the CEO and upper management including a half retarded CCO, explaining how this is a "marathon" and not a "sprint", and how they knew this was not going to be easy and they need and want everyone to stick around for the long haul because "Rome wasn't built in a day", the leadership team grants thousands more options to the field begging managers to tell their reps not to quit. Just hang with us, this will be huge.

    December 2016: Granted many more thousands of shares, plus a 5 figure retention bonus - almost everyone was already looking for a new job, and decided to stop since they were begging people to stick around despite the idiotic strategic plan set forth by this organization of clowns. Only a few smart people see the writing on the wall and leave. Others, could really care less and just want to see what happens because it's just so damn pathetic, kind of like picking a scab.

    January 3, 2017: VP of Sales fired, and in a pathetic display of our unprofessionalism, the chief commercial officer (who is not even smart enough to be a field sales representative) explains it on a conference call and literally craps over who was a very well liked person. The VP of Sales was really the only reason most stuck around this long. Everyone sees the writing on the wall now.

    A couple weeks ago: Layoffs, keeping only the people dumb enough to stick around. More than likely, all of those will be quitting soon anyways based on the display of corporate integrity shown throughout the existence of a commercial organization and the utter foolishness of the people still running the show.

    To those looking for a job, if you take this one, you will be looking again very soon. This is your warning. These are the people you are dealing with.
     

  2. anonymous

    anonymous Guest

    Half retarded CCO???
     
  3. anonymous

    anonymous Guest

    Sad but true.....
     
  4. anonymous

    anonymous Guest

    You forgot to mention Dino Lunch!!
     
  5. anonymous

    anonymous Guest

    Dino Lunch has convinced DW and DK there is reimbursment everywhere and it's a people problem. How she wasn't fired after launch for incompetence of knowing the market or lack of is incredible. Just look at the history of Optimer and their stupid reimbursment strategy that allowed Cubist to buy them for pennies on the dollar. Let's recycle the same strategy to see what happens! Now knowing it's a people problem after every person hired was a top performer for an entire career it will be interesting to see what happens. Let's get ENT device reps with relationships and they will solve the reimbursment issue that is included in the case rate! I guess compliance has changed from reps not being in cases and now promoting on job boards they have a code for an off label use of swimmers ear. Reps do your homework on this company.

    - Ask which insurances are actually paying? Do they have documentation from the fantastic hub?
    - is the j-code to be used in the case rate procedure even loaded in the state your asked to work?
    - what percent of cases are done in hospital vs ASC because there is little to no ASC payment because it contracted. There is nearly no hospital business to be had if you ask docs the real numbers.
    - ask how many involved in trial studies use the product. You will find 2(Omaha and LA).
    Docs who want to use can't even get it. 30 times the cost of generic standard drops with no data and reimbursment.
    - ask where the price point came from? Why would they price this product to the minimum to get a J-code to target Medicaid 340b hospitals?

    That's just a few to get started
     
  6. anonymous

    anonymous Guest

    Sales continue to Plummet!! This week in the 60's NATIONWIDE!!! thanks Dina!
     
  7. anonymous

    anonymous Guest

    In order to plummet they would need to begin from a high level. A couple hundred thousand in sales nationwide in a quarter is not exactly a high level, hence, no plummeting. Otiprio is a dead end and everyone knows it.
     
  8. anonymous

    anonymous Guest

    Future reps ask how the former ENT reps with great relations did selling Otiprio. Also ask about the former Pacira "rockstar" in DC who was let go. You will find the best relationships in the world will not matter when there is little or no reimbursment for a product 30 times more expensive than the standard of care.
     
  9. anonymous

    anonymous Guest

    Thanks to Dino Lunch, she single handedly ruined the company and the careers of many. CLUELESS!
     
  10. anonymous

    anonymous Guest

    Looks like it must be a real people problem with continued poor numbers. It couldn't be there is no reimbursment for a case rate product and nearly all the surgeries are done in ASC's. I'm sure David's new Pacira "friends" will get it fixed. The new manager for the west has never been a manager or been in a children's hospital so that should help!! I wonder what the spin for DW on the next investor call will be?
     
  11. anonymous

    anonymous Guest

    The people running this company couldn't find water if they fell out of a boat. Pathetic idiots.
     
  12. anonymous

    anonymous Guest

    This place has destroyed relationships with ENT's, who are the nicest physicians to work with!!! So Sad! Sales have not improved at all, and nothing has changed, but they are spending a fortune flying around all of these useless home office people, who have not helped at all,( hello Iris, Dean). Where is the board?
    Dave Weber needs to be fired.
     
  13. anonymous

    anonymous Guest

    So the new East manager that was with the company for just over a week quit. It Didn't take that ENT device manager to long figure out the lies they are telling people. The West manager with no experience who worked with VP in past is still there because he need the title for his resume. Don't believe the lies that there is reimbursment and cases in the hospital to be had. Ask about the great new comp plan that they just rolled out. Classic
     
  14. anonymous

    anonymous Guest

    Any rep that goes here didn't do their homework talking to ENT's about where they do their volume of surgeries and need for the big "O". I guess now DK has his puppets in Matt and Abby talking to potential reps because they will tell them the false reality to the viability of each territory. It's funny that the ENT manager quit after a week!!
     
  15. anonymous

    anonymous Guest

    14% growth over 4th qtr 2016 reported today. Worst qtr over qtr growth reported since launch even with a J code. Selling a few hundred more vials in the height of tube season in all the facilities with access is not a win. Nothing new coming out until 2018!! All ENT reps encouraged to board the Titanic!!
     
  16. anonymous

    anonymous Guest

    Next quarter, right Dave Weber? Your phD must be in stupidity. The group of losers in sales and sales management are only one upped by the complete dipshits in reimbursement. Good luck, losers!
     
  17. anonymous

    anonymous Guest

    Otonomy blew thru $13 million in the quarter on selling expenses and sold $380K. Has to be the most
    brilliant management team in the industry! Please give yourself some more options to congratulate yourselves
    on the stellar performance!! SOS!!!
     
  18. anonymous

    anonymous Guest

    Dave you should offer options and retention to the sales team after the great 1st qtr earnings call. I'm sure it would be sweet to get even more you can reissue yourself after you have them fired now that the board meeting is happening soon.
     
  19. anonymous

    anonymous Guest

    Getting your popcorn and get ready for shitshow part II. New reps going to get trained up and get out there and find there is no reimbursment and surgeries done in hospitals. Kaplan now will have the bullseye from Dino Lunch! Don't have to worry about formulary reviews and access to product. Should be a simple sell!!